Back to 
Duquesne Family Office LLC
Duquesne Family Office LLC
PTGX4 quarters
Position history for Duquesne Family Office LLC's holdings in PROTAGONIST THERAPEUTICS INC
Yes. Duquesne Family Office holds 208,900 shares of PTGX (Protagonist Therapeutics), worth $25.6M, as of its Q2 2026 13F filing. It increased the position by 49,200 shares (+30.8%) from Q1 2026. Duquesne Family Office has held PTGX since Q3 2025, across 4 quarterly 13F filings. PTGX is 0.5% of Duquesne Family Office's reported 13F portfolio.
Current Value
$25.6M
Current Shares
208,900
Total Value Change
+$15M
Total Shares Change
+49,200
Quarter-by-Quarter History
Other major holders of PTGX: BlackRock, Inc., FARALLON CAPITAL MANAGEMENT, L.L.C.